VKTX Stock Recent News

On Tuesday, Viking Therapeutics Inc. VKTX released the much-awaited data from its Phase 2 trial of VK2735 pill, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Viking Therapeutics on Tuesday announced that a trial showed its oral weight-loss drug works — and like a larger rival, its stock price immediately suffered.

Viking Therapeutics stock (NASDAQ: VKTX) plunged 37% in pre-market trading on Tuesday following the release of much-anticipated results from its mid-stage trial for the oral weight loss drug VK2735. The drop, which deepened as premarket trading commenced, surprised some investors, especially as the company touted statistically significant weight loss results in the study.

Viking Therapeutics said on Tuesday its experimental weight-loss pill helped patients with obesity lose nearly 12.2% of their body weight on average over 13 weeks in a mid-stage study.

Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as Compared to Placebo Up to 12.2% (26.6 lbs) Mean Weight Loss Observed After 13 Weeks of VK2735 Treatment Compared with 1.3% (2.9 lbs) for Placebo Exploratory Assessment of Low Dose Maintenance Treatment Demonstrates Positive Proof of Concept VK2735 Shown to be Safe and Well-Tolerated in 13-Week Study; 99% of GI-specific Treatment Emergent Adverse Events Considered Mild or Moderate Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO , Aug. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and gl

Viking Therapeutics offers a speculative opportunity, driven by its promising obesity drug pipeline and the massive potential of the GLP-1 market. Early clinical data for VK2735 is competitive, even outperforming some current leaders, though longer trials are needed for direct comparison. Risks remain high—failure in late-stage trials could mean near-total loss, but the pipeline's progress and additional MASH drug offer some risk mitigation.

Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (VKTX 5.07%) stock higher on the first trading day of the week.

Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies.

Investing successfully in biopharmaceutical companies can sometimes require complicated calculations worthy of Albert Einstein's brain. That's because picking the right ones involves a variation of the theory of relativity.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?